echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Active Ingredient News
    Yingli Pharmaceutical's linperlisib Phase 2 results are gratifying, and many domestic pharmaceutical companies deploy PI3K inhibitors

    (abbreviated as Yingli Pharmaceutical) announced its self-developed new drug Linperlisib (YY-20394) for the treatment of relapsed/refractory follicular lymphoma (r/r) FL) Phase 2 registration clinical trials are initially completed .

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.